🇺🇸 ImmunityBio, Inc.
Forum topic · IBRX · Company page: financials, ownership and filings
Join the discussion on ImmunityBio, Inc.
Loading…
Results announced on 9 November 2026
ImmunityBio, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $49 million (up 52% from a year earlier) and a net loss of $185 million.
Insider trading in October 2026
Directors and officers of ImmunityBio, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $1,119,848 in 2 trades.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 160 funds hold $750 million
160 mutual funds in 2 countries hold shares of ImmunityBio, Inc. worth $750 million, about 8.4% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 118 funds added shares and 43 sold; on balance they bought $104 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.